Navigation Links
'Reassuring' findings released in national study of influenza vaccine safety in pregnancy
Date:9/23/2013

SAN DIEGO, CA Researchers from Boston University's Slone Epidemiology Center and UC San Diego, in collaboration with the American Academy of Allergy Asthma and Immunology (AAAAI), have found 'reassuring' evidence of the H1N1 influenza vaccine's safety during pregnancy. The national study, which was launched shortly after the pandemic H1N1 influenza outbreak of 2009 and funded by the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), will be summarized in two companion papers published online this month in the journal, Vaccine.

Despite federal health authorities' recommendations that all pregnant women be vaccinated for influenza in order to avoid serious complications of flu infection, it is estimated that fewer than 50 percent of women follow this advice, largely because they were concerned about the effects flu vaccines might have on the developing baby. Since it was anticipated that the 2009 pandemic H1N1 influenza outbreak could be particularly severe, it was important to gather data on the safety of this vaccine in pregnancy. Therefore, a national study was launched by the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS), a collaboration between investigative teams at Boston University and UC San Diego, and coordinated by the American Academy of Allergy, Asthma and Immunology.

One investigative team, from Boston University, interviewed 4,191 mothers from four regional centers in the U.S. who had either delivered a baby with one of 41 specific birth defects or delivered an infant without defects. They compared the use of influenza vaccine in the two groups during the 2009 - 2011 seasons. In their analysis of birth defects, Dr. Carol Louik, ScD, lead investigator of the BU team, stated "We found no evidence of an increase in risk for the most commonly-occurring specific major birth defects, which were the focus of the study, if a woman received the flu shot in pregnancy. Concerns about the risk of specific birth defects was a critical question that has not been considered very much until now, and our data are reassuring."

The team also compared the risk of preterm delivery in vaccinated versus unvaccinated women. While the team did observe a slight increase in preterm delivery rates among pregnant women who received the H1N1 vaccine specifically during the 2009 - 2010 season, vaccinated women overall only delivered an average of two days earlier compared to the unvaccinated group. For those vaccinated during the 2010 - 2011 season, the situation was reversed, and vaccinated women were less likely to deliver a preterm baby.

The other VAMPSS research team from UC San Diego followed 1,032 pregnant women across the U.S. and Canada who either chose to receive an influenza vaccine or were not vaccinated during one of the three seasons from 2009 - 2012. Women were recruited through MotherToBaby, a service of the non-profit Organization of Teratology Information Specialists (OTIS) that provides counseling to the public about pregnancy and breastfeeding exposures. Researchers found that women vaccinated during pregnancy were no more likely to experience miscarriage, have a baby born with a birth defect, or have a baby born smaller than normal compared with those who did not receive a vaccination. In addition, those who were vaccinated delivered infants three days earlier than unvaccinated women.

"The overall results of the study were quite reassuring about the safety of the flu vaccine formulations that contained the pandemic H1N1 strain given in these three seasons," said Christina Chambers, PhD, lead investigator of UC San Diego's team. "We believe our study's results can help women and their doctors become better informed about the benefits and risks of vaccination during pregnancy."


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass.
2. Surprising findings on hydrogen production in green algae
3. Findings to help in design of drugs against virus causing childhood illnesses
4. ACMG releases report on incidental findings in clinical exome and genome sequencing
5. New findings in the search for genetic clues to insulin production
6. The findings between DNMs and autism provides global view of mutability on human diseases
7. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
8. Verinata Health Announces New Findings At The American Society Of Human Genetics
9. New findings on gene regulation and bone development
10. New findings on protein misfolding
11. Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a ... conditions, today announced that Linda Marbán, Ph.D, president and chief ... conferences: Cowen and Company 37th Annual ... ET Boston, MA ... am PT (12:00 pm ET) Dana Point, CA ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... ... announced that is has acquired Kendall Research Systems, LLC (KRS) clinical ... (MIT) that develops neural interface technology for research and clinical applications. The terms ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... development of precision treatments for neurodegenerative diseases, today announced it has issued a ... approach.” This is one of a series of commentaries from ProMIS’s scientific team ...
(Date:2/22/2017)... Feb. 22, 2017 Aethlon Medical, Inc. (Nasdaq: ... a study that validated the ability of the Aethlon ... with increased mortality in immune-suppressed sepsis patients and also ... The objective of the study was to validate ... Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) ...
Breaking Biology Technology: